Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

56.26 -0.55 (-0.98%)
Streaming Delayed Price Updated: 1:24 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
67 68 Next >
Negotiation or Coercion? Big Pharma and US Chamber of Commerce Tackle Government on Drug Prices
The U.S. Chamber of Commerce has filed a lawsuit against the federal government, challenging a recent law that grants Medicare the authority to negotiate drug prices with pharmaceutical companies. 
Via Benzinga
This Drug Candidate Could Be a Winner for Bristol Myers
Bristol Myers' lung cancer drug candidate could be just months away from U.S. Food and Drug Administration approval. 
Via The Motley Fool
Bristol Myers Squibb Receives U.S. FDA Approval of New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, Massachusetts
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023
From Bristol Myers Squibb
Via Business Wire
Looking At Bristol-Myers Squibb's Recent Unusual Options Activity
Via Benzinga
Pharmaceutical Giant Merck Challenges Inflation Reduction Act over Medicare Drug Pricing, Calls It 'Extortion'
Merck & Co Inc (NYSE: MRK) has reportedly filed a lawsuit against the U.S. government to halt implementing the Medicare drug price negotiation program outlined in the Inflation Reduction Act (IRA).  
Via Benzinga
Chipotle, Bristol-Myers Squibb, Corteva And A Healthcare Giant On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Brenda Vingiello of Sand Hill Global Advisors named CVS Health Corporation (NYSE: CVS) 
Via Benzinga
Bristol Myers' Opdivo/Chemo Shows Durable Results At Four Years In Lung Cancer Patients
Via Benzinga
Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
Is Bristol Myers Squibb a Top Dividend Stock?
Its hefty yield isn't the only reason to consider buying this top pharma stock. 
Via The Motley Fool
Bristol Myers' CAR T Cell Therapy Shows Deep, Durable Efficacy In Blood Cancer Patients
Via Benzinga
Biotechs Zeroing In on Developing Breakthrough Therapeutics for Metastatic Breast Cancer
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NASDAQ:RAIN),(NASDAQ:CNSP),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
3 Dividend Stocks You Can Buy Without Any Hesitation
The choices are easy with these stocks. 
Via The Motley Fool
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Bristol-Myers Squibb Unusual Options Activity
Via Benzinga
BioNTech Surges On This Promising Update In Its Bid To Take On Bristol Myers In Lung Cancer Treatment
BioNTech is testing out a next-generation form of Yervoy, hoping to reduce side effects. 
Via Investor's Business Daily
3 Top Stocks That Just Went on Sale
These are dependable companies, and their shares are at prices worth buying. 
Via The Motley Fool
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Hold R&D Day on September 14
From Bristol Myers Squibb
Via Business Wire
Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Admin 
Via MarketBeat
Topics Death
Exposures Death Product Safety
Bristol Myers Squibb to Present Late-Breaking Data for Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 International Conference on Malignant Lymphoma
From Bristol Myers Squibb
Via Business Wire
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expre...
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) is First and Only CAR T to Deliver Deep and Durable Efficacy in Pivotal Multicenter Trial in Relapsed or Refractory Chronic Lymphocytic Leukemia, Based on Data Presented at ASCO 2023
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl® (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
From Bristol Myers Squibb
Via Business Wire
Mirati's Sitravatinib Flunks Phase 3 Combo Therapy Study In Type Of Lung Cancer Setting
Via Benzinga
Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
From Bristol Myers Squibb
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Doximity is an Overlooked Medical Ecosystem AI Play
Doximity Inc. (NASDAQ: DOCS) is a digital professional social network platform for medical practitioners. It’s a medical community networking platform like 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.